Create account

Coverage dated November 1, 2023

Wegovy Maker Novo Nordisk’s Profit Surges on Weight-Loss-Drug Demand

Headline from Wall Street Journal

Novo Nordisk reported soaring profit, boosted by blockbuster weight-loss drugs that have quickly made the Danish drugmaker Europe’s most valuable company.

Wall Street Journal's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

5 articles, oldest first.

  1. CNN

    Novo Nordish and Eli Lilly cash in on blockbuster weight-loss drugs (opens CNN)

    Published

    CNN's feed description

    On Thursday, Novo Nordisk, the company behind Ozempic and Wegovy, reported a 29% increase in sales to $8.4 billion for the third quarter. Eli Lilly, which makes diabetes drug Mounjaro, reported a 37% revenue increase to $9.5 billion in the third quarter.

  2. Wall Street Journal

    Wegovy Maker Novo Nordisk’s Profit Surges on Weight-Loss-Drug Demand (opens Wall Street Journal)

    Published

    Wall Street Journal's feed description

    Novo Nordisk reported soaring profit, boosted by blockbuster weight-loss drugs that have quickly made the Danish drugmaker Europe’s most valuable company.

  3. Digital Journal

    Anti-obesity drugs fatten Novo Nordisk profits (opens Digital Journal)

    Published

    Digital Journal's feed description

    Danish drugmaker Novo Nordisk reported Thursday a sharp rise in third quarter sales and profits driven by the success of its anti-diabetes and

  4. The Guardian

    Sales soar at Danish firm behind weight-loss drug semaglutide (opens The Guardian)

    Published

    The Guardian's feed description

    Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

Wegovy Maker Novo Nordisk’s Profit Surges on Weight-Loss-Drug Demand | Since Then